Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension
Primary Purpose
Postnatal Hypertension
Status
Unknown status
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Labetalol
Nifedipine
Sponsored by

About this trial
This is an interventional treatment trial for Postnatal Hypertension focused on measuring postpartum hypertension, labetalol in postpartum hypertension, nifedipine in postpartum hypertension
Eligibility Criteria
Inclusion Criteria:
- all women with postpartum hypertension as a continuation of pregnancy induced hypertension,eclampsia, pre-eclampsia or new onset de-novo postpartum hypertension,of any parity.
- age group between 18-48.
- after informed consent.
Exclusion Criteria:
- all women with chronic hypertension, uncontrolled and un treated medical disorders will be excluded.
- conditions in which drugs labetalol and nifedipine is contraindicated.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
group A
group B
Arm Description
tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
Outcomes
Primary Outcome Measures
Blood Pressure less than 140/90 mm of hg
less than 140/90 mm of hg
Secondary Outcome Measures
Full Information
NCT ID
NCT02426177
First Posted
April 21, 2015
Last Updated
April 23, 2015
Sponsor
Dow University of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT02426177
Brief Title
Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension
Official Title
Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
May 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dow University of Health Sciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To compare effectiveness of oral labetalol and oral nifedipine for management of postpartum hypertension.
Detailed Description
A comparison of oral labetalol and oral nifedipine for management of postpartum hypertension. Which drug is more effective in lowering blood pressures in patient with postpartum hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postnatal Hypertension
Keywords
postpartum hypertension, labetalol in postpartum hypertension, nifedipine in postpartum hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
98 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
group A
Arm Type
Active Comparator
Arm Description
tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
Arm Title
group B
Arm Type
Active Comparator
Arm Description
tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
Intervention Type
Drug
Intervention Name(s)
Labetalol
Intervention Description
anti-hypertensive agents
Intervention Type
Drug
Intervention Name(s)
Nifedipine
Intervention Description
calcium channel blocker ,for lowering blood pressure
Primary Outcome Measure Information:
Title
Blood Pressure less than 140/90 mm of hg
Description
less than 140/90 mm of hg
Time Frame
24 hours
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
48 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
all women with postpartum hypertension as a continuation of pregnancy induced hypertension,eclampsia, pre-eclampsia or new onset de-novo postpartum hypertension,of any parity.
age group between 18-48.
after informed consent.
Exclusion Criteria:
all women with chronic hypertension, uncontrolled and un treated medical disorders will be excluded.
conditions in which drugs labetalol and nifedipine is contraindicated.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
fariha javed, mbbs
Phone
923009298708
Email
farihajaved207@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
fariha javed, mbbs
Organizational Affiliation
Dow University of Health Sciences
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension
We'll reach out to this number within 24 hrs